Clinical Trials Browser

Terminated × INDUSTRY × givinostat × Clear all

NCT00496431 2022-01-27

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Phase 1/2 Terminated

Hodgkin Disease